I-CHUN CHENCHING-HUNG LINYEN-SHEN LU2020-05-252020-05-2520110098-7484https://www.scopus.com/inward/record.uri?eid=2-s2.0-79958031307&doi=10.1001%2fjama.2011.751&partnerID=40&md5=e9a048b7082493a39e55cf84b1b436cchttps://scholars.lib.ntu.edu.tw/handle/123456789/494593[SDGs]SDG3antineoplastic agent; axillary lymph node extirpation; breast cancer; cancer adjuvant therapy; cancer recurrence; clinical practice; clinical trial (topic); disease free survival; human; intermethod comparison; letter; lymph node dissection; lymph node metastasis; optimal drug dose; overall survival; postoperative care; priority journal; recurrence free survival; sentinel lymph node dissection; sentinel lymph node metastasis; surgical approach; survival; adjuvant chemotherapy; axilla; breast tumor; drug administration; female; lymphadenectomy; note; reproducibility; sentinel lymph node biopsy; time; treatment outcome; Axilla; Breast Neoplasms; Chemotherapy, Adjuvant; Clinical Trials as Topic; Disease-Free Survival; Drug Administration Schedule; Female; Humans; Lymph Node Excision; Reproducibility of Results; Sentinel Lymph Node Biopsy; Time Factors; Treatment Outcomeletter10.1001/jama.2011.751216426712-s2.0-79958031307